OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 326,700 Shares of Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 326,700 shares of the company’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $23.04, for a total value of $7,527,168.00. Following the sale, the director owned 6,536,764 shares of the company’s stock, valued at approximately $150,607,042.56. The trade was a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

OrthoPediatrics Price Performance

Shares of NASDAQ:KIDS opened at $23.00 on Wednesday. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $600.53 million, a PE ratio of -13.69 and a beta of 0.98. The firm has a 50 day moving average of $21.61 and a 200-day moving average of $18.76. OrthoPediatrics Corp. has a 12 month low of $14.42 and a 12 month high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. On average, equities research analysts predict that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after purchasing an additional 645 shares during the period. Millennium Management LLC raised its stake in OrthoPediatrics by 55.3% during the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock worth $16,172,000 after buying an additional 233,873 shares during the period. Goldman Sachs Group Inc. boosted its holdings in OrthoPediatrics by 112.3% in the first quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock worth $4,937,000 after acquiring an additional 106,041 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of OrthoPediatrics during the first quarter valued at approximately $389,000. Finally, American Century Companies Inc. grew its position in OrthoPediatrics by 12.5% in the 2nd quarter. American Century Companies Inc. now owns 34,486 shares of the company’s stock valued at $741,000 after purchasing an additional 3,828 shares during the period. 69.05% of the stock is owned by institutional investors.

OrthoPediatrics News Summary

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Analysts assigned OrthoPediatrics a consensus price target of $26.44, implying potential upside from recent trading levels and signaling continued confidence in the company’s long-term growth prospects. OrthoPediatrics Receives $26.44 Consensus Price Target
• Neutral Sentiment: The reported sales appear across related director, major-shareholder and beneficial-ownership filings, meaning some transactions may represent overlapping disclosures rather than entirely separate blocks of stock. After the transactions, the reporting holders still controlled approximately 6.53 million shares, indicating continued substantial exposure to KIDS. SEC Insider Transaction Filing
• Negative Sentiment: Director David R. Pelizzon and major shareholder Jennifer N. Pritzker reported sales of 326,700 shares on August 28 at an average price of $23.04, worth approximately $7.53 million. Each reduced their reported ownership by 4.76%, which may pressure the stock or raise concerns about insider confidence, although both retained large positions. SEC Major Shareholder Ownership Filing
• Negative Sentiment: The same holders, along with Squadron Capital LLC, reported additional sales of 10,131 shares on September 1 at $23.10, worth approximately $234,000 per reported transaction. The small 0.15% ownership reduction is less significant by itself, but reinforces the near-term insider-selling overhang. SEC Ownership Filing

Analysts Set New Price Targets

Several analysts have recently weighed in on KIDS shares. Piper Sandler restated an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Needham & Company LLC lifted their target price on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Finally, Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $26.44.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.